MedPath

Morphine

Generic Name
Morphine
Brand Names
Arymo, Avinza, Doloral, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex
Drug Type
Small Molecule
Chemical Formula
C17H19NO3
CAS Number
57-27-2
Unique Ingredient Identifier
76I7G6D29C

Overview

Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone. Morphine was granted FDA approval in 1941.

Background

Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone. Morphine was granted FDA approval in 1941.

Indication

Morphine is used for the management of chronic, moderate to severe pain. Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.

Associated Conditions

  • Chronic Pain
  • Severe Pain

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2024/06/28
Phase 4
Not yet recruiting
2024/06/21
Phase 2
Recruiting
2024/06/18
Phase 3
Recruiting
2024/06/13
Phase 4
Completed
Yuwei Qiu
2024/05/20
Not Applicable
Completed
2024/05/16
Phase 2
Recruiting
Kasr El Aini Hospital
2024/05/13
Phase 4
Recruiting
2024/05/10
Not Applicable
Recruiting
2024/04/29
Early Phase 1
Recruiting
2024/04/03
Phase 2
Recruiting
Dalin Tzu Chi General Hospital

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Bryant Ranch Prepack
63629-2302
ORAL
20 mg in 1 mL
1/6/2022
Sun Pharmaceutical Industries, Inc.
63304-451
ORAL
30 mg in 1 1
12/14/2023
Fresenius Kabi USA, LLC
76045-005
INTRAVENOUS, INTRAMUSCULAR
4 mg in 1 mL
8/31/2020
Piramal Critical Care, Inc.
66794-162
EPIDURAL, INTRATHECAL
500 mg in 20 mL
12/27/2023
Par Pharmaceutical Inc.
49884-670
ORAL
100 mg in 1 1
2/19/2015
Precision Dose, Inc.
68094-256
ORAL
100 mg in 5 mL
6/30/2023
Rhodes Pharmaceuticals L. P.
42858-802
ORAL
30 mg in 1 1
12/31/2023
Physicians Total Care, Inc.
54868-5590
ORAL
100 mg in 1 1
3/7/2011
Purdue Pharma LP
59011-262
ORAL
60 mg in 1 1
3/23/2017
Hospira, Inc.
0409-1134
INTRAVENOUS
50 mg in 1 mL
10/13/2021

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath